Analysis Pharmacovigilance

Medline's bed recall remedy plan shows how device harm data becomes continued-use guidance

Medline's updated repair-and-replace programme follows seven deaths and 35 serious injuries. For PV teams, the case is a lesson in turning harm reports into actionable advice.

VigiEye editorial · Mon 16 Nov 2026

What happened

On 13 November 2026, FDA's MedWatch recall channel carried an update from Medline on its repair and replace programme for recalled beds, rails, mattresses and accessories. The company has updated its guidance on continued use and on remedies for all of its branded beds and accessories. The recall concerns fire and entrapment risks, which the notice links to seven deaths and 35 serious injuries.

The record is short. It does not set out what the repair or replacement involves, how long it will take, how many units are affected, or which interim precautions Medline advises while products stay in service. Those details sit in the underlying notice, and readers should consult it directly rather than rely on summaries. What the record does establish is the scope (all Medline-branded beds and accessories), the two hazards (fire and entrapment) and the severity of the reported harm.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Sources this analysis is based on

Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.

More analysis & opinionAll →